Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial

被引：18

作者：

Asakura, Masanori ^{[1
,2
]}

Ito, Shin ^{[2
]}

Yamada, Takahisa ^{[3
]}

Saito, Yoshihiko ^{[4
]}

Kimura, Kazuo ^{[5
]}

Yamashina, Akira ^{[6
]}

Hirayama, Atsushi ^{[7
,34
]}

Kobayashi, Youichi ^{[8
]}

Hanatani, Akihisa ^{[9
,34
]}

Tsujimoto, Mitsuru ^{[10
]}

Yasuda, Satoshi ^{[11
]}

Abe, Yukio ^{[12
]}

Higashino, Yorihiko ^{[13
,34
]}

Tamaki, Yodo ^{[14
]}

Sugino, Hiroshi ^{[15
,16
]}

Niinuma, Hiroyuki ^{[17
]}

Okuhara, Yoshitaka ^{[1
]}

Koitabashi, Toshimi ^{[18
]}

Momomura, Shin-Ichi ^{[19
]}

Asai, Kuniya ^{[20
]}

Nomura, Akihiro ^{[21
]}

Kawai, Hiroya ^{[22
,35
]}

Satoh, Yasuhiro ^{[23
]}

Yoshikawa, Tsutomu ^{[24
]}

Hirata, Ken-Ichi ^{[25
]}

Yokoi, Yoshiaki ^{[26
]}

Tanaka, Jun ^{[27
,28
]}

Shibata, Yoshisato ^{[29
]}

Maejima, Yasuhiro ^{[30
]}

Tamaki, Shunsuke ^{[3
]}

Kawata, Hiroyuki ^{[4
,35
]}

Iwahashi, Noriaki ^{[5
]}

Kobayashi, Masatake ^{[6
]}

Higuchi, Yoshiharu ^{[7
,34
]}

Kada, Akiko ^{[31
]}

Yamamoto, Haruko ^{[32
]}

Kitakaze, Masafumi ^{[2
,33
]}

机构：

[1] Hyogo Coll Med, Dept Cardiovasc & Renal Med, Nishinomiya, Hyogo, Japan

[2] Natl Cerebral & Cardiovasc Ctr, Dept Clin Med & Dev, Osaka, Japan

[3] Osaka Gen Med Ctr, Div Cardiol, Osaka, Japan

[4] Nara Med Univ, Nara Med Univ Hosp, Dept Cardiovasc Med, Nara, Japan

[5] Yokohama City Univ, Med Ctr, Div Cardiol, Yokohama, Kanagawa, Japan

[6] Tokyo Med Univ, Dept Cardiol, Tokyo, Japan

[7] Nihon Univ, Itabashi Hosp, Dept Med, Div Cardiol, Tokyo, Japan

[8] Showa Univ Hosp, Dept Med, Div Cardiol, Tokyo, Japan

[9] Osaka City Univ, Grad Sch Med, Dept Cardiovasc Med, Osaka, Japan

[10] Veritas Hosp, Cardiovasc Ctr, Dept Cardiol, Kawanishi, Hyogo, Japan

[11] Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Med, Osaka, Japan

[12] Osaka City Gen Hosp, Dept Cardiol, Osaka, Japan

[13] Higashi Takarazuka Satoh Hosp, Dept Cardiol, Takarazuka, Hyogo, Japan

[14] Tenri Hosp, Dept Cardiol, Tenri, Nara, Japan

[15] Natl Hosp Org Kure Med Ctr, Dept Cardiac Surg, Hiroshima, Japan

[16] Chugoku Canc Ctr, Hiroshima, Japan

[17] St Lukes Int Hosp, Dept Cardiol, Tokyo, Japan

[18] Kitasato Univ, Sch Med, Dept Cardiovasc Med, Tokyo, Japan

[19] Jichi Med Univ, Saitama Med Ctr, Cardiovasc Div, Saitama, Japan

[20] Chiba Hokusoh Hosp, Nippon Med Sch, Dept Cardiovasc Med, Chiba, Japan

[21] Kanazawa Univ, Grad Sch Med Sci, Dept Cardiovasc & Internal Med, Kanazawa, Ishikawa, Japan

[22] Hyogo Brain & Heart Ctr, Hyogo Prefectural Himeji Cardiovasc Ctr, Div Cardiovasc Med, Himeji, Hyogo, Japan

[23] Natl Hosp Org Disaster Med Ctr, Dept Cardiol, Tokyo, Japan

[24] Sakakibara Heart Inst, Dept Cardiol, Tokyo, Japan

[25] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc Med, Kobe, Hyogo, Japan

[26] Kishiwada Tokushukai Hosp, Cardiac Arrhythmia Ctr, Dept Med, Kishiwada, Osaka, Japan

[27] Tokyo Metropolitan Geriatr Hosp, Dept Cardiol, Tokyo, Japan

[28] Inst Gerontol, Tokyo, Japan

[29] Miyazaki Med Assoc Hosp, Dept Cardiol, Miyazaki, Japan

[30] Tokyo Med & Dent Univ, Med Hosp, Dept Cardiovasc Med, Tokyo, Japan

[31] Natl Hosp Org Nagoya Med Ctr, Dept Clin Res Management, Nagoya, Aichi, Japan

[32] Natl Cerebral & Cardiovasc Ctr, Dept Adv Med Technol Dev, 6-1 Kishibeshinmachi, Suita, Osaka 5648565, Japan

[33] Hanwa Daini Senboku Hosp, Naka Ku, 3176 Fukaikitamachi, Sakai, Osaka 5998271, Japan

[34] Osaka Police Hosp, Osaka, Japan

[35] Nara Prefectural Gen Med Ctr, Nara, Japan

来源：

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2022年 / 8卷 / 02期

关键词：

Mineralocorticoid receptor antagonist; Acute heart failure; Eplerenone; ANGIOTENSIN-ALDOSTERONE SYSTEM; MYOCARDIAL-INFARCTION; MORTALITY; HOSPITALIZATION; SPIRONOLACTONE; DYSFUNCTION; GUIDELINES; EMPHASIS; OUTCOMES; BLOCKER;

D O I：

10.1093/ehjcvp/pvaa132

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aims A mineralocorticoid receptor antagonist (MRA) is effective in patients with chronic heart failure; however, the effects of the early initiation of an MRA in patients with acute heart failure (AHF) have not been elucidated. Methods and results In this multicentre, randomized, double-blind, placebo-controlled, parallel-group study, we focused on the safety and effectiveness of the treatment with eplerenone, a selective MRA in 300 patients with AHF, that is, 149 in the eplerenone group and 151 in the placebo group in 27 Japanese institutions. The key inclusion criteria were (i) patients aged 20 years or older and (ii) those with left ventricular ejection fraction of <= 40%. The primary outcome was a composite of cardiac death or first re-hospitalization due to cardiovascular disease within 6 months. The mean age of the participants was 66.8 years, 27.3% were women, and the median levels of brain natriuretic peptide were 376.0 pg/mL. The incidences of the primary outcome were 19.5% in the eplerenone group and 17.2% in the placebo group [hazard ratio (HR): 1.09, 95% confidence interval (CI): 0.642-1.855]. In prespecified secondary outcomes, HR for the composite endpoint, cardiovascular death, or first re-hospitalization due to heart failure within 6 months was 0.55 (95% CI: 0.213-1.434). The safety profile for eplerenone was as expected. Conclusion The early initiation of eplerenone in patients with AHF could safely be utilized. The reduction of the incidence of a composite of cardiovascular death or first re-hospitalization for cardiovascular diseases by eplerenone is inconclusive because of inadequate power.

引用

页码：108 / 117

页数：10

共 50 条

[1] Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER)
Asakura, Masanori
Yamamoto, Haruko
Asai, Kuniya
Hanatani, Akihisa
Hirata, Ken-ichi
Hirayakma, Atsushi
Kimura, Kazuo
Kobayashi, Youichi
Momomura, Shin-ichi
Nakagawa, Yoshihisa
Nishi, Yutaro
Saito, Yoshihiko
Satoh, Yasuhiro
Yamada, Takahisa
Yamashina, Akira
Yasuda, Satoshi
Yoshikawa, Tsutomu
Kada, Akiko
Uesaka, Hiroyuki
Kitakaze, Masafumi
CARDIOVASCULAR DRUGS AND THERAPY, 2015, 29 (02) : 179 - 185
[2] Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER)
Masanori Asakura
Haruko Yamamoto
Kuniya Asai
Akihisa Hanatani
Ken-ichi Hirata
Atsushi Hirayakma
Kazuo Kimura
Youichi Kobayashi
Shin-ichi Momomura
Yoshihisa Nakagawa
Yutaro Nishi
Yoshihiko Saito
Yasuhiro Satoh
Takahisa Yamada
Akira Yamashina
Satoshi Yasuda
Tsutomu Yoshikawa
Akiko Kada
Hiroyuki Uesaka
Masafumi Kitakaze
Cardiovascular Drugs and Therapy, 2015, 29 : 179 - 185
[3] Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF)
Tsutsui, Hiroyuki
Ito, Hiroshi
Kitakaze, Masafumi
Komuro, Issei
Murohara, Toyoaki
Izumi, Tohru
Sunagawa, Kenji
Yasumura, Yoshio
Yano, Masafumi
Yamamoto, Kazuhiro
Yoshikawa, Tsutomu
Tsutamoto, Takayoshi
Zhang, Junwei
Okayama, Akifumi
Ichikawa, Yoshihiko
Kanmuri, Kazuhiro
Matsuzaki, Masunori
CIRCULATION JOURNAL, 2018, 82 (01) : 148 - +
[4] Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)
Gheorghiade, Mihai
Albaghdadi, Mazen
Zannad, Faiez
Fonarow, Gregg C.
Boehm, Michael
Gimpelewicz, Claudio
Botha, Jaco
Moores, Shelley
Lewis, Eldrin F.
Rattunde, Henning
Maggioni, Aldo
EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (01) : 100 - 106
[5] Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double-Blind, Randomized, Placebo-Controlled Trial
Sudano, Isabella
Naegele, Matthias
Roas, Susanne
Periat, Daniel
Frank, Michelle
Kouroedov, Alexey
Noll, Georg
Luscher, Thomas F.
Enseleit, Frank
Ruschitzka, Frank
Flammer, Andreas J.
CLINICAL CARDIOLOGY, 2016, 39 (05) : 285 - 290
[6] Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial
Raman, Subha V.
Hor, Kan N.
Mazur, Wojciech
Halnon, Nancy J.
Kissel, John T.
He, Xin
Tam Tran
Smart, Suzanne
McCarthy, Beth
Taylor, Michael D.
Jefferies, John L.
Rafael-Fortney, Jill A.
Lowe, Jeovanna
Roble, Sharon L.
Cripe, Linda H.
LANCET NEUROLOGY, 2015, 14 (02) : 153 - 161
[7] Ursodeoxycholic Acid in Patients With Chronic Heart Failure A Double-Blind, Randomized, Placebo-Controlled, Crossover Trial
von Haehling, Stephan
Schefold, Joerg C.
Jankowska, Ewa A.
Springer, Jochen
Vazir, Ali
Kalra, Paul R.
Sandek, Anja
Fauler, Guenter
Stojakovic, Tatjana
Trauner, Michael
Ponikowski, Piotr
Volk, Hans-Dieter
Doehner, Wolfram
Coats, Andrew J. S.
Poole-Wilson, Philip A.
Anker, Stefan D.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (06) : 585 - 592
[8] Efficacy of naproxen in patients with sciatica: multicenter, randomized, double-blind, placebo-controlled trial
Grovle, Lars
Hasvik, Eivind
Holst, Rene
Saetre, Anders
Brox, Jens Ivar
Mathiassen, Stale
Myhre, Kjersti
Holmgard, Thor Einar
Haugen, Anne Julsrud
PAIN, 2024, 165 (11) : 2606 - 2614
[9] Efficacy and safety of nortriptyline in functional dyspepsia in Asians: A randomized double-blind placebo-controlled trial
Kaosombatwattana, Uayporn
Pongprasobchai, Supot
Limsrivilai, Julajak
Maneerattanaporn, Monthira
Leelakusolvong, Somchai
Tanwandee, Tawesak
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (02) : 411 - 417
[10] Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
Tomaschitz, Andreas
Fahrleitner-Pammer, Astrid
Pieske, Burkert
Verheyen, Nicolas
Amrein, Karin
Ritz, Eberhard
Kienreich, Katharina
Horina, Joerg H.
Schmidt, Albrecht
Kraigher-Krainer, Elisabeth
Colantonio, Caterina
Meinitzer, Andreas
Pilz, Stefan
BMC ENDOCRINE DISORDERS, 2012, 12

← 1 2 3 4 5 →